Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma

NCT00838955 is registered in ClinicalTrials.gov with Loyola University as lead sponsor.

NCT NCT00838955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00838955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Lead sponsor
Loyola University
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2009
Completion date
October 31, 2017
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin's lymphoma